Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

The clinical impact of donor-specific antibodies on antibody-mediated rejection and long-term prognosis after heart transplantation.

Su JA, Baxter-Lowe LA, Kantor PF, Szmuszkovicz JR, Menteer J.

Curr Opin Organ Transplant. 2019 Jun;24(3):245-251. doi: 10.1097/MOT.0000000000000636.

PMID:
31090631
2.

The clinical impact of donor-specific antibodies on antibody-mediated rejection and long-term prognosis after heart transplantation.

Su JA, Baxter-Lowe LA, Kantor PF, Szmuszkovicz JR, Menteer J.

Curr Opin Organ Transplant. 2019 Apr 9. doi: 10.1097/MOT.0000000000000636. [Epub ahead of print]

PMID:
30973410
3.

The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.

Hochberg J, Zahler S, Geyer MB, Chen N, Krajewski J, Harrison L, Militano O, Ozkaynak MF, Cheerva AC, Talano J, Moore TB, Gillio AP, Walters MC, Baxter-Lowe LA, Hamby C, Cairo MS.

Bone Marrow Transplant. 2019 Feb;54(2):226-235. doi: 10.1038/s41409-018-0247-9. Epub 2018 Jun 13.

PMID:
29899571
4.

Pulmonary function after hematopoietic stem cell transplantation is significantly better in pediatric recipients following reduced toxicity compared with myeloablative conditioning.

Majzner R, Sandoval C, Dozor AJ, Jin Z, van de Ven C, Dalal R, Morris E, Harrison L, Wolownik K, Fabricatore S, Baxter-Lowe LA, Cairo MS.

Bone Marrow Transplant. 2016 Nov;51(11):1530-1532. doi: 10.1038/bmt.2016.172. Epub 2016 Jun 20. No abstract available.

PMID:
27322849
5.

CPRA for allocation of kidneys in the US: More candidates ≥98% CPRA, lower positive crossmatch rates and improved transplant rates for sensitized patients.

Baxter-Lowe LA, Kucheryavaya A, Tyan D, Reinsmoen N.

Hum Immunol. 2016 May;77(5):395-402. doi: 10.1016/j.humimm.2016.03.003. Epub 2016 Mar 21.

PMID:
27012168
6.

A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.

Zahler S, Bhatia M, Ricci A, Roy S, Morris E, Harrison L, van de Ven C, Fabricatore S, Wolownik K, Cooney-Qualter E, Baxter-Lowe LA, Luisi P, Militano O, Kletzel M, Cairo MS.

Biol Blood Marrow Transplant. 2016 Apr;22(4):698-704. doi: 10.1016/j.bbmt.2016.01.019. Epub 2016 Jan 16.

7.

High-Resolution HLA Typing for Sensitized Patients: Advances in Medicine and Science Require Us to Challenge Existing Paradigms.

Duquesnoy RJ, Gebel HM, Woodle ES, Nickerson P, Baxter-Lowe LA, Bray RA, Claas FH, Eckels DD, Friedewald JJ, Fuggle SV, Gerlach JA, Fung JJ, Kamoun M, Middleton D, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A.

Am J Transplant. 2015 Oct;15(10):2780-1. doi: 10.1111/ajt.13376. Epub 2015 Jul 14. No abstract available.

8.

Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level?

Duquesnoy RJ, Kamoun M, Baxter-Lowe LA, Woodle ES, Bray RA, Claas FH, Eckels DD, Friedewald JJ, Fuggle SV, Gebel HM, Gerlach JA, Fung JJ, Middleton D, Nickerson P, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A.

Am J Transplant. 2015 Apr;15(4):923-30. doi: 10.1111/ajt.13167. Epub 2015 Mar 16.

9.

Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1.

Fleischhauer K, Fernandez-Viña MA, Wang T, Haagenson M, Battiwalla M, Baxter-Lowe LA, Ciceri F, Dehn J, Gajewski J, Hale GA, Heemskerk MB, Marino SR, McCarthy PL, Miklos D, Oudshoorn M, Pollack MS, Reddy V, Senitzer D, Shaw BE, Waller EK, Lee SJ, Spellman SR.

Bone Marrow Transplant. 2014 Sep;49(9):1176-83. doi: 10.1038/bmt.2014.122. Epub 2014 Jun 23.

10.

Center-defined unacceptable HLA antigens facilitate transplants for sensitized patients in a multi-center kidney exchange program.

Baxter-Lowe LA, Cecka M, Kamoun M, Sinacore J, Melcher ML.

Am J Transplant. 2014 Jul;14(7):1592-8. doi: 10.1111/ajt.12734. Epub 2014 Jun 16.

11.

Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.

Bhatia M, Jin Z, Baker C, Geyer MB, Radhakrishnan K, Morris E, Satwani P, George D, Garvin J, Del Toro G, Zuckerman W, Lee MT, Licursi M, Hawks R, Smilow E, Baxter-Lowe LA, Schwartz J, Cairo MS.

Bone Marrow Transplant. 2014 Jul;49(7):913-20. doi: 10.1038/bmt.2014.84. Epub 2014 May 5.

PMID:
24797180
12.

Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia.

McGuinn C, Geyer MB, Jin Z, Garvin JH, Satwani P, Bradley MB, Bhatia M, George D, Duffy D, Morris E, van de Ven C, Schwartz J, Baxter-Lowe LA, Cairo MS.

Pediatr Blood Cancer. 2014 Jul;61(7):1289-94. doi: 10.1002/pbc.24976. Epub 2014 Feb 12.

PMID:
24623601
13.

Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation.

Fernandez-Viña MA, Wang T, Lee SJ, Haagenson M, Aljurf M, Askar M, Battiwalla M, Baxter-Lowe LA, Gajewski J, Jakubowski AA, Marino S, Oudshoorn M, Marsh SG, Petersdorf EW, Schultz K, Turner EV, Waller EK, Woolfrey A, Umejiego J, Spellman SR, Setterholm M.

Blood. 2014 Feb 20;123(8):1270-8. doi: 10.1182/blood-2013-10-532671. Epub 2014 Jan 9.

14.

Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy.

Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, Arcese W, Barker JN, Baxter-Lowe LA, Brown M, Fernandez-Vina MA, Freeman J, He W, Iori AP, Horowitz MM, Locatelli F, Marino S, Maiers M, Michel G, Sanz GF, Gluckman E, Rocha V; Center for International Blood and Marrow Transplant Research, Netcord, Eurocord, and the European Group for Blood and Marrow Transplantation.

Blood. 2014 Jan 2;123(1):133-40. doi: 10.1182/blood-2013-05-506253. Epub 2013 Oct 18.

15.

Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.

Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Viña M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, Palmer J, Prasad VK, Reddy V, Ringden O, Saber W, Santarone S, Schultz KR, Setterholm M, Trachtenberg E, Turner EV, Woolfrey AE, Lee SJ, Anasetti C.

Blood. 2013 Nov 21;122(22):3651-8. doi: 10.1182/blood-2013-05-501510. Epub 2013 Aug 27.

16.

Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation.

Fernández-Viña MA, Klein JP, Haagenson M, Spellman SR, Anasetti C, Noreen H, Baxter-Lowe LA, Cano P, Flomenberg N, Confer DL, Horowitz MM, Oudshoorn M, Petersdorf EW, Setterholm M, Champlin R, Lee SJ, de Lima M.

Blood. 2013 May 30;121(22):4603-10. doi: 10.1182/blood-2013-02-481945. Epub 2013 Apr 17.

17.

Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.

Radhakrishnan K, Bhatia M, Geyer MB, Del Toro G, Jin Z, Baker C, Harrison L, Morris E, Baxter-Lowe LA, Cairo MS.

Biol Blood Marrow Transplant. 2013 Apr;19(4):676-7. doi: 10.1016/j.bbmt.2013.02.002. Epub 2013 Feb 9. No abstract available.

18.

Dynamic challenges inhibiting optimal adoption of kidney paired donation: findings of a consensus conference.

Melcher ML, Blosser CD, Baxter-Lowe LA, Delmonico FL, Gentry SE, Leishman R, Knoll GA, Leffell MS, Leichtman AB, Mast DA, Nickerson PW, Reed EF, Rees MA, Rodrigue JR, Segev DL, Serur D, Tullius SG, Zavala EY, Feng S.

Am J Transplant. 2013 Apr;13(4):851-860. doi: 10.1111/ajt.12140. Epub 2013 Feb 7.

19.

Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients.

Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH, George D, Bradley MB, Harrison L, Petrillo K, Schwartz J, Foley S, Hawks R, Baxter-Lowe LA, Cairo MS.

Biol Blood Marrow Transplant. 2013 Apr;19(4):552-61. doi: 10.1016/j.bbmt.2012.12.005. Epub 2012 Dec 16.

20.

Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34(+) cells and a fixed CD3(+) dose.

Dvorak CC, Gilman AL, Horn B, Oon CY, Dunn EA, Baxter-Lowe LA, Cowan MJ.

Bone Marrow Transplant. 2013 Apr;48(4):508-13. doi: 10.1038/bmt.2012.186. Epub 2012 Nov 26.

PMID:
23178543
21.

Beta-adrenergic receptor polymorphisms and cardiac graft function in potential organ donors.

Khush KK, Pawlikowska L, Menza RL, Goldstein BA, Hayden V, Nguyen J, Kim H, Poon A, Sapru A, Matthay MA, Kwok PY, Young WL, Baxter-Lowe LA, Zaroff JG.

Am J Transplant. 2012 Dec;12(12):3377-86. doi: 10.1111/j.1600-6143.2012.04266.x. Epub 2012 Sep 20.

22.

Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy.

Rocha V, Spellman S, Zhang MJ, Ruggeri A, Purtill D, Brady C, Baxter-Lowe LA, Baudoux E, Bergamaschi P, Chow R, Freed B, Koegler G, Kurtzberg J, Larghero J, Lecchi L, Nagler A, Navarrette C, Prasad V, Pouthier F, Price T, Ratanatharathorn V, van Rood JJ, Horowitz MM, Gluckman E, Eapen M; Eurocord-European Blood and Marrow Transplant Group and the Center for International Blood and Marrow Transplant Research.

Biol Blood Marrow Transplant. 2012 Dec;18(12):1890-6. doi: 10.1016/j.bbmt.2012.07.010. Epub 2012 Jul 17.

23.

The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.

Le Gall JB, Milone MC, Waxman IM, Shaw LM, Harrison L, Duffy D, van de Ven C, Militano O, Geyer MB, Morris E, Bhatia M, Satwani P, George D, Garvin JH, Bradley MB, Schwartz J, Baxter-Lowe LA, Cairo MS.

Bone Marrow Transplant. 2013 Jan;48(1):19-25. doi: 10.1038/bmt.2012.105. Epub 2012 Jun 11.

PMID:
22684047
24.

Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.

Law J, Cowan MJ, Dvorak CC, Musick L, Long-Boyle JR, Baxter-Lowe LA, Horn B.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1656-63. doi: 10.1016/j.bbmt.2012.05.006. Epub 2012 May 15.

25.

The 4G/4G genotype of the PAI-1 (serpine-1) 4G/5G polymorphism is associated with decreased lung allograft utilization.

Sapru A, Zaroff JG, Pawlikowska L, Liu KD, Khush KK, Baxter-Lowe LA, Hayden V, Menza RL, Convery M, Lo V, Poon A, Kim H, Young WL, Kukreja J, Matthay MA; DOGMATIC Study Investigators.

Am J Transplant. 2012 Jul;12(7):1848-54. doi: 10.1111/j.1600-6143.2012.03996.x. Epub 2012 Mar 5.

26.

T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients.

Geyer MB, Ricci AM, Jacobson JS, Majzner R, Duffy D, Van de Ven C, Ayello J, Bhatia M, Garvin JH Jr, George D, Satwani P, Harrison L, Morris E, Semidei-Pomales M, Schwartz J, Alobeid B, Baxter-Lowe LA, Cairo MS.

Br J Haematol. 2012 Apr;157(2):205-19. doi: 10.1111/j.1365-2141.2012.09048.x. Epub 2012 Feb 8.

PMID:
22313507
27.

A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.

Satwani P, Bhatia M, Garvin JH Jr, George D, Dela Cruz F, Le Gall J, Jin Z, Schwartz J, Duffy D, van de Ven C, Foley S, Hawks R, Morris E, Baxter-Lowe LA, Cairo MS.

Biol Blood Marrow Transplant. 2012 Feb;18(2):324-9. doi: 10.1016/j.bbmt.2011.11.007. Epub 2011 Nov 9.

28.

Scoring HLA class I mismatches by HistoCheck does not predict clinical outcome in unrelated hematopoietic stem cell transplantation.

Spellman S, Klein J, Haagenson M, Askar M, Baxter-Lowe LA, He J, Hsu S, Blasczyk R, Hurley C.

Biol Blood Marrow Transplant. 2012 May;18(5):739-46. doi: 10.1016/j.bbmt.2011.09.008. Epub 2011 Sep 29.

29.

Maternal microchimerism in pediatric inflammatory bowel disease.

Suskind DL, Kong D, Stevens A, Wahbeh G, Christie D, Baxter-Lowe LA, Muench MO.

Chimerism. 2011 Apr;2(2):50-4. doi: 10.4161/chim.2.2.16556.

30.

A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.

Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C, Satwani P, Bhatia M, Garvin JH, Bradley MB, Harrison L, Morris E, Della-Latta P, Schwartz J, Baxter-Lowe LA, Cairo MS.

Br J Haematol. 2011 Oct;155(2):218-34. doi: 10.1111/j.1365-2141.2011.08822.x. Epub 2011 Aug 16.

31.

HLA-DR matching in organ allocation: balance between waiting time and rejection in pediatric kidney transplantation.

Vu LT, Baxter-Lowe LA, Garcia J, McEnhill M, Summers P, Hirose R, Lee M, Stock PG.

Arch Surg. 2011 Jul;146(7):824-9. doi: 10.1001/archsurg.2011.147.

PMID:
21768429
32.

Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.

Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A, Isola L, Baxter-Lowe LA, Kelly M, Owzar K, Linker C; Cancer and Leukemia Group B.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1395-403. doi: 10.1016/j.bbmt.2011.01.016. Epub 2011 Feb 3.

33.

A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.

Styczynski J, Tallamy B, Waxman I, van de Ven C, Milone MC, Shaw LM, Harrison L, Morris E, Satwani P, Bhatia M, George D, Bradley MB, Garvin JH, Schwartz J, Baxter-Lowe LA, Cairo MS.

Bone Marrow Transplant. 2011 Jun;46(6):790-9. doi: 10.1038/bmt.2010.209. Epub 2010 Sep 6.

PMID:
20818441
34.

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).

Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe LA, Devine S, Farag S, Hurd D, Ball E, McCarthy P, Lister J, Shea TC, Linker C.

Biol Blood Marrow Transplant. 2011 Apr;17(4):558-65. doi: 10.1016/j.bbmt.2010.07.015. Epub 2010 Jul 30.

35.

Kidney transplantation at UCSF: 8,300 transplants and onward.

Wojciechowski D, Hirose R, Stock P, Vincenti F, Baxter-Lowe LA, Salvatierra O.

Clin Transpl. 2010:161-7.

PMID:
21696039
36.

Advancement and clinical implications of HLA typing in allogeneic hematopoietic stem cell transplantation.

Baxter-Lowe LA, Hurley CK.

Cancer Treat Res. 2009;144:71-94. doi: 10.1007/978-0-387-78580-6_4. Review. No abstract available.

PMID:
19779873
37.

HLA-A disparities illustrate challenges for ranking the impact of HLA mismatches on bone marrow transplant outcomes in the United States.

Baxter-Lowe LA, Maiers M, Spellman SR, Haagenson MD, Wang T, Fernandez-Vina M, Marsh SG, Horowitz M, Hurley CK.

Biol Blood Marrow Transplant. 2009 Aug;15(8):971-81. doi: 10.1016/j.bbmt.2009.04.015.

38.

Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions.

Dvorak CC, Gilman AL, Horn B, Jaroscak J, Dunn EA, Baxter-Lowe LA, Cowan MJ.

Bone Marrow Transplant. 2009 Dec;44(12):805-12. doi: 10.1038/bmt.2009.87. Epub 2009 May 4.

PMID:
19421175
39.

Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies.

Horn B, Soni S, Khan S, Petrovic A, Breslin N, Cowan M, Pelle-Day G, Cooperstein E, Baxter-Lowe LA.

Bone Marrow Transplant. 2009 Mar;43(6):469-76. doi: 10.1038/bmt.2008.339. Epub 2008 Oct 27.

PMID:
18955982
40.

Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.

Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD Jr, Barlogie B, van Rhee F.

Br J Haematol. 2008 Dec;143(5):641-53. doi: 10.1111/j.1365-2141.2008.07340.x. Epub 2008 Oct 16.

41.

Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning.

Waxman IM, Militano O, Baldinger L, Roman E, Qualter E, Morris E, Garvin J, Bradley MB, Bhatia M, Satwani P, George D, Del Toro G, Hawks R, Wolownik K, Foley S, Cheung YK, Schwartz J, van de Ven C, Baxter-Lowe LA, Cairo MS.

Pediatr Transplant. 2009 Jun;13(4):464-74. doi: 10.1111/j.1399-3046.2008.01000.x. Epub 2008 Sep 10.

PMID:
18785912
42.

Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies.

Kurtzberg J, Prasad VK, Carter SL, Wagner JE, Baxter-Lowe LA, Wall D, Kapoor N, Guinan EC, Feig SA, Wagner EL, Kernan NA; COBLT Steering Committee.

Blood. 2008 Nov 15;112(10):4318-27. doi: 10.1182/blood-2007-06-098020. Epub 2008 Aug 21.

43.

Strategies and technical challenges in allele level Class II typing in 2578 bone marrow transplantation donor-recipient pairs.

Williams TM, Winden T, Setterholm M, Vierra-Green CA, Spellman S, Flesch S, Awdeh Z, Baxter-Lowe LA, Begovich AB, Fernandez-Vina M, Hegland J, Hurley CK, Johnson D, Noreen H, Salazar M, Schmeckpeper B, Yunis EJ.

Hum Immunol. 2008 Apr-May;69(4-5):227-34. doi: 10.1016/j.humimm.2008.03.004. Epub 2008 Apr 25.

PMID:
18486756
44.

Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders.

Ozyurek E, Cowan MJ, Koerper MA, Baxter-Lowe LA, Dvorak CC, Horn BN.

Bone Marrow Transplant. 2008 Jul;42(2):83-91. doi: 10.1038/bmt.2008.89. Epub 2008 Apr 7.

PMID:
18391990
45.

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C.

Blood. 2007 Dec 15;110(13):4576-83. Epub 2007 Sep 4.

PMID:
17785583
46.

Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases.

Bradley MB, Satwani P, Baldinger L, Morris E, van de Ven C, Del Toro G, Garvin J, George D, Bhatia M, Roman E, Baxter-Lowe LA, Schwartz J, Qualter E, Hawks R, Wolownik K, Foley S, Militano O, Leclere J, Cheung YK, Cairo MS.

Bone Marrow Transplant. 2007 Oct;40(7):621-31. Epub 2007 Jul 30.

PMID:
17660841
47.

A high degree of HLA disparity arises from limited allelic diversity: analysis of 1775 unrelated bone marrow transplant donor-recipient pairs.

Hurley CK, Fernandez-Vina M, Hildebrand WH, Noreen HJ, Trachtenberg E, Williams TM, Baxter-Lowe LA, Begovich AB, Petersdorf E, Selvakumar A, Stastny P, Hegland J, Hartzman RJ, Carston M, Gandham S, Kollman C, Nelson G, Spellman S, Setterholm M.

Hum Immunol. 2007 Jan;68(1):30-40. Epub 2006 Oct 25.

PMID:
17207710
48.

Induction of tolerance to composite tissue allograft in a rat model.

Quatra F, Lowenberg DW, Buncke HJ, Romeo OM, Brooks D, Buntic RF, Baxter-Lowe LA.

Microsurgery. 2006;26(8):573-8.

PMID:
17091475
49.

Tracking microchimeric DNA in plasma to diagnose and manage organ transplant rejection.

Baxter-Lowe LA, Busch MP.

Clin Chem. 2006 Apr;52(4):559-61. No abstract available.

50.

Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide.

Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, Baxter-Lowe LA.

J Exp Med. 2006 Apr 17;203(4):961-71. Epub 2006 Apr 3.

Supplemental Content

Loading ...
Support Center